A Phase I/II Trial of Ibrutinib (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Carfilzomib (Primary) ; Ibrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 21 Jul 2017 Planned End Date changed from 1 May 2018 to 1 May 2019.
- 21 Jul 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 06 Dec 2016 Status changed from recruiting to active, no longer recruiting.